FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

THON RICHARD 		2. Issuer Name and Ticker or Trading Symbol

ProUroCare Medical Inc. [ PUMD ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

8351 WEST LAKE DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/3/2011
(Street)

CHANHASSEN, MN 55317
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock options   $1.00                      (2) 7/11/2015   Common stock, $0.00001 par value   35000     35000   D    
Stock options   $11.33                      (1) 4/18/2012   Common stock, $0.00001 par value   2000     2000   D    
Stock options   $11.33                      (1) 4/18/2012   Common stock, $0.00001 par value   1000     1000   I   Options held by son, Eric Thon  
Stock Options   $0.85                      (1) 3/3/2016   Common stock, $0.00001 par value   45000     45000   D    
Stock options   $1.50                      (3) 9/29/2016   Common stock, $0.00001 par value   60000     60000   D    
Stock options   $0.975   5/3/2011     A      90000         (4) 5/4/2018   Common stock, $0.00001 par value   90000   $0   90000   D    

Explanation of Responses:
( 1)  Immediately exercisable.
( 2)  Exercisable as to 26,666 shares immediately; remaining options vest as to 8,334 shares on July 1, 2011.
( 3)  Options shall vest on the latter of the date that the Company is cleared by the FDA to sell the ProUroScan System in the United States or the date the Company closes on an aggregate of $2,000,000 or more of incremental equity financing after the date of grant(including the exercise of existing warrants).).
( 4)  The options will vest in the amounts indicated below upon achievement of the following objectives within nine months of the Company's receipt of FDA clearance to sell the ProUroScan System in the U.S.:25% vesting - upon recording $500,000 in sales, 15% vesting upon the raising of $5 million in new funding, 30% vesting upon the execution of a corporate partner agreement, 30% vesting upon the filing of three new patent applications

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
THON RICHARD
8351 WEST LAKE DRIVE
CHANHASSEN, MN 55317

Chief Financial Officer

Signatures
Richard B. Thon 5/5/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more ProUroCare Medical (CE) Charts.
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more ProUroCare Medical (CE) Charts.